SEC Form 4 · accession 0001104659-16-159822

Aegerion Pharmaceuticals, Inc. · AEGR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Nov 29, 2016

Accepted (ET)

Nov 30, 2016 · 7:48 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001338042

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Nov 29, 2016	D	10,000	—	D	0	D
Common Stock^F2,F3	Nov 29, 2016	D	521,350	—	D	0	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (Right to Buy)^F4	$17.64	Nov 29, 2016	D	9,988	D	Jun 1, 2014	Jun 1, 2021	Common Stock	9,988	D
Stock Option (Right to Buy)^F4	$15.00	Nov 29, 2016	D	12,854	D	Jun 5, 2015	Jun 5, 2022	Common Stock	12,854	D
Stock Option (Right to Buy)^F4	$64.73	Nov 29, 2016	D	14,700	D	Jun 26, 2014	Jun 26, 2023	Common Stock	14,700	D
Stock Option (Right to Buy)^F4	$32.55	Nov 29, 2016	D	5,012	D	Jun 26, 2015	Jun 26, 2024	Common Stock	5,012	D
Stock Option (Right to Buy)^F4	$17.98	Nov 29, 2016	D	18,000	D	Jun 26, 2016	Jun 26, 2025	Common Stock	18,000	D

F1Disposed of in exchange for 10,256 common shares of Novelion Therapeutics Inc. ("Novelion") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
F2Disposed of in exchange for 534,696 common shares of Novelion pursuant to the Merger Agreement.
F3Shares were held by Scheer Investment Holdings VII, LLC. The Reporting Person is the managing member of Scheer Investment Holdings VII, LLC. Mr. Scheer disclaimed beneficial ownership of such shares except to the extent of his proportionate pecuniary interest therein.
F4Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.